Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
---|---|---|---|---|---|
CA5-C82E9 | Cynomolgus | Biotinylated Cynomolgus CA125 / MUC16 Protein, His,Avitag™ (MALS verified) |
|
||
CA5-M52H6 | Mouse | Mouse CA125 / MUC16 Protein, His Tag (MALS verified) | |||
CA5-C52H8 | Cynomolgus | Cynomolgus CA125 / MUC16 Protein, His Tag (MALS verified) |
|
||
CA5-R52H3 | Rhesus macaque | Rhesus macaque CA125 / MUC16 (12664-12920) Protein, His Tag (MALS verified) |
|
||
CA5-R52H6 | Rhesus macaque | Rhesus macaque CA125 / MUC16 (13647-14291) Protein, His Tag (MALS verified) |
|
||
CA5-H52H6 | Human | Human CA125 / MUC16 (13810-14451) Protein, His Tag (MALS verified) |
|
||
CA5-H82F8 | Human | Biotinylated Human CA125 / MUC16 (13810-14451) Protein, Fc,Avitag™ |
|
||
CA5-H82F4 | Human | Biotinylated Human CA125 / MUC16 Protein, Fc,Avitag™ |
|
Biotinylated Mouse Mesothelin, His,Avitag (Cat. No. MSN-M82E7) immobilized on CM5 Chip can bind Mouse CA125 Protein, His Tag (Cat. No. CA5-M52H6) with an affinity constant of 16.4 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Oregovomab | B43.13 | Phase 3 Clinical | Paladin Pharma | Ovarian Neoplasms; Carcinoma; Abdominal Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Adenocarcinoma | Details |
LBL-033 | LBL-033 | Phase 2 Clinical | Nanjing Leads Biolabs Co Ltd | Neoplasms | Details |
REGN-5668 | REGN-5668 | Phase 2 Clinical | Ovarian Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms | Details | |
Ubamatamab | REGN-4018 | Phase 2 Clinical | Ovarian Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms | Details | |
PRGN-3005 | PRGN-3005 | Phase 1 Clinical | Precigen Inc | Ovarian Neoplasms; Esophageal Neoplasms; Sarcoma; Peritoneal Neoplasms; Lymphoma, Non-Hodgkin; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms | Details |
JCAR-020 | JCAR-020 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center, Juno Therapeutics Inc, Eureka Therapeutics Inc | Solid tumours; Neoplasms | Details |
huAR9.6-IRDye800 | University Of Nebraska Medical Center | Details | |||
Oregovomab | B43.13 | Phase 3 Clinical | Paladin Pharma | Ovarian Neoplasms; Carcinoma; Abdominal Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Adenocarcinoma | Details |
LBL-033 | LBL-033 | Phase 2 Clinical | Nanjing Leads Biolabs Co Ltd | Neoplasms | Details |
REGN-5668 | REGN-5668 | Phase 2 Clinical | Ovarian Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms | Details | |
Ubamatamab | REGN-4018 | Phase 2 Clinical | Ovarian Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms | Details | |
PRGN-3005 | PRGN-3005 | Phase 1 Clinical | Precigen Inc | Ovarian Neoplasms; Esophageal Neoplasms; Sarcoma; Peritoneal Neoplasms; Lymphoma, Non-Hodgkin; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms | Details |
JCAR-020 | JCAR-020 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center, Juno Therapeutics Inc, Eureka Therapeutics Inc | Solid tumours; Neoplasms | Details |
huAR9.6-IRDye800 | University Of Nebraska Medical Center | Details |
This web search service is supported by Google Inc.